Difference between revisions of "Endometrial cancer - null regimens"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "https://www.gynecologiconcology-online.net/article/S0090-8258(03)00863-1" to "https://doi.org/10.1016/j.ygyno.2003.11.048")
m
Line 10: Line 10:
  
 
==Placebo==
 
==Placebo==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 19: Line 19:
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[http://clincancerres.aacrjournals.org/content/25/8/2424 Kitson et al. 2018 (PREMIUM)]
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6586555/ Kitson et al. 2018 (PREMIUM)]
 
|2015-2017
 
|2015-2017
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
Line 27: Line 27:
 
|}
 
|}
 
''No active antineoplastic treatment prior to surgery.''
 
''No active antineoplastic treatment prior to surgery.''
 +
<div class="toccolours" style="background-color:#cbd5e8">
 
====Subsequent treatment====
 
====Subsequent treatment====
 
*[[Surgery#Endometrial_cancer_surgery|Surgery]]
 
*[[Surgery#Endometrial_cancer_surgery|Surgery]]
−
 
+
</div></div>
 
===References===
 
===References===
−
# '''PREMIUM:''' Kitson SJ, Maskell Z, Sivalingam VN, Allen JL, Ali S, Burns S, Gilmour K, Latheef R, Slade RJ, Pemberton PW, Shaw J, Ryder WD, Kitchener HC, Crosbie EJ. PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial. Clin Cancer Res. 2019 Apr 15;25(8):2424-2432. Epub 2018 Dec 18. [http://clincancerres.aacrjournals.org/content/25/8/2424 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30563932 PubMed] ISRCTN88589234
+
# '''PREMIUM:''' Kitson SJ, Maskell Z, Sivalingam VN, Allen JL, Ali S, Burns S, Gilmour K, Latheef R, Slade RJ, Pemberton PW, Shaw J, Ryder WD, Kitchener HC, Crosbie EJ. PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial. Clin Cancer Res. 2019 Apr 15;25(8):2424-2432. Epub 2018 Dec 18. [http://clincancerres.aacrjournals.org/content/25/8/2424 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6586555/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30563932 PubMed] ISRCTN88589234
  
 
=Adjuvant therapy=
 
=Adjuvant therapy=
  
 
==Observation==
 
==Observation==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 71: Line 72:
 
|}
 
|}
 
''No further treatment.''
 
''No further treatment.''
 +
<div class="toccolours" style="background-color:#cbd5e8">
 
====Preceding treatment====
 
====Preceding treatment====
 
*GOG 20, GOG 99, MaNGO ILIADE-III: [[Surgery#Endometrial_cancer_surgery|Surgery]]
 
*GOG 20, GOG 99, MaNGO ILIADE-III: [[Surgery#Endometrial_cancer_surgery|Surgery]]
Line 76: Line 78:
 
====Subsequent treatment====
 
====Subsequent treatment====
 
*MaNGO ILIADE-III: [[Endometrial_cancer#Radiation_therapy|RT]]
 
*MaNGO ILIADE-III: [[Endometrial_cancer#Radiation_therapy|RT]]
 +
</div></div>
 
===References===
 
===References===
 
# '''GOG 20:''' Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, Beecham J, Park R, Silverberg S. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1985 Sep;3(9):1240-5. [https://doi.org/10.1200/JCO.1985.3.9.1240 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3897471 PubMed]
 
# '''GOG 20:''' Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, Beecham J, Park R, Silverberg S. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1985 Sep;3(9):1240-5. [https://doi.org/10.1200/JCO.1985.3.9.1240 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3897471 PubMed]
Line 83: Line 86:
  
 
==Placebo==
 
==Placebo==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 100: Line 103:
 
|}
 
|}
 
''No active antineoplastic treatment. Note that this trial was stopped early due to the increased risk of ERT in the Women's Health Initiative trial, and should be considered inconclusive.''
 
''No active antineoplastic treatment. Note that this trial was stopped early due to the increased risk of ERT in the Women's Health Initiative trial, and should be considered inconclusive.''
 +
<div class="toccolours" style="background-color:#cbd5e8">
 
====Preceding treatment====
 
====Preceding treatment====
 
*[[Surgery#Endometrial_cancer_surgery|Hysterectomy]]
 
*[[Surgery#Endometrial_cancer_surgery|Hysterectomy]]
 +
</div></div>
 
===References===
 
===References===
 
# '''GOG 137A:''' Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS; Gynecologic Oncology Group. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Feb 1;24(4):587-92. [https://doi.org/10.1200/jco.2005.02.8464 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16446331/ PubMed] NCT00002976
 
# '''GOG 137A:''' Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS; Gynecologic Oncology Group. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Feb 1;24(4):587-92. [https://doi.org/10.1200/jco.2005.02.8464 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16446331/ PubMed] NCT00002976
Line 109: Line 114:
  
 
==Placebo==
 
==Placebo==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 125: Line 130:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 
====Preceding treatment====
 
====Preceding treatment====
 
*[[Regimen_classes#Platinum-based_regimen|Platinum-based chemotherapy]]
 
*[[Regimen_classes#Platinum-based_regimen|Platinum-based chemotherapy]]
−
 
+
</div></div>
 
===References===
 
===References===
 
# '''DUO-E:''' NCT04269200
 
# '''DUO-E:''' NCT04269200

Revision as of 03:46, 25 February 2023

Back to Top

The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main endometrial cancer page for current regimens.


Neoadjuvant therapy

Placebo

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Kitson et al. 2018 (PREMIUM) 2015-2017 Phase 3 (C) Metformin Did not meet primary endpoint of posttreatment IHC expression of Ki-67

No active antineoplastic treatment prior to surgery.

Subsequent treatment

References

  1. PREMIUM: Kitson SJ, Maskell Z, Sivalingam VN, Allen JL, Ali S, Burns S, Gilmour K, Latheef R, Slade RJ, Pemberton PW, Shaw J, Ryder WD, Kitchener HC, Crosbie EJ. PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial. Clin Cancer Res. 2019 Apr 15;25(8):2424-2432. Epub 2018 Dec 18. link to original article link to PMC article PubMed ISRCTN88589234

Adjuvant therapy

Observation

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Omura et al. 1985 (GOG 20) 1973-1982 Phase 3 (C) Doxorubicin Did not meet efficacy endpoints
Keys et al. 2004 (GOG 99) 1987-1995 Phase 3 (C) RT Inferior RFS
Hogberg et al. 2010 (EORTC 55991) 1996-2007 Phase 3 (C) 1. Cisplatin & Doxorubicin
2. Cisplatin & Epirubicin
3. Epirubicin & Paclitaxel
4. Carboplatin & Doxorubicin
5. Carboplatin & Paclitaxel 		Seems to have inferior PFS
Hogberg et al. 2010 (MaNGO ILIADE-III) 1998-2007 Phase 3 (C) Cisplatin & Doxorubicin Did not meet primary endpoint of PFS

No further treatment.

Preceding treatment

Subsequent treatment

  • MaNGO ILIADE-III: RT

References

  1. GOG 20: Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, Beecham J, Park R, Silverberg S. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1985 Sep;3(9):1240-5. link to original article PubMed
  2. GOG 99: Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG; Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Mar;92(3):744-51. Erratum in: Gynecol Oncol. 2004 Jul;94(1):241-2. link to original article PubMed
  3. EORTC 55991: Hogberg T, Signorelli M, Freire de Oliveira C, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer. 2010 Sep;46(13):2422-31. Epub 2010 Jul 7. link to original article link to PMC article PubMed NCT00005583
  4. MaNGO ILIADE-III: Hogberg T, Signorelli M, Freire de Oliveira C, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer. 2010 Sep;46(13):2422-31. Epub 2010 Jul 7. link to original article link to PMC article PubMed

Placebo

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Barakat et al. 2006 (GOG 137A) 1997-2003 Phase 3 (C) Estrogen replacement therapy Did not meet primary endpoint of RFS

No active antineoplastic treatment. Note that this trial was stopped early due to the increased risk of ERT in the Women's Health Initiative trial, and should be considered inconclusive.

Preceding treatment

References

  1. GOG 137A: Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS; Gynecologic Oncology Group. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Feb 1;24(4):587-92. link to original article PubMed NCT00002976
  2. SIENDO: NCT03555422

Maintenance after first-line therapy

Placebo

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Awaiting publication (DUO-E) 2020-ongoing Phase 3 (C) 1. Durvalumab
2. Durvalumab & Olaparib 		TBD

Preceding treatment

References

  1. DUO-E: NCT04269200
Retrieved from "https://hemonc.org/w/index.php?title=Endometrial_cancer_-_null_regimens&oldid=66427"